SAN DIEGO, Jan. 7, 2018 /PRNewswire/ — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced an update on its business performance, including preliminary sales results for 2017 and key program initiatives for 2018. Kevin Gorman, CEO of Neurocrine, will discuss these updates as part…